https://www.thebodypro.com/author/edwin-de-jesus
Edwin DeJesus, M.D. Img

Edwin DeJesus, M.D.

Dr. DeJesus is a graduate from the University of Puerto Rico, School of Medicine. He completed his Internal Medicine training and Infectious Disease fellowship at the Medical College of Pennsylvania in Philadelphia and is board certified in Infectious Diseases. He has been a fellow of the American College of Physicians since 1996. Dr. DeJesus is the medical director for the Orlando Immunology Center (OIC) in downtown Orlando and maintains a secondary office with Infectious Disease Consultants (IDC) in Altamonte Springs, Fla. Since 1993, Dr. DeJesus has devoted most of his time to caring for HIV and hepatitis-infected patients. He is also deeply involved in HIV-related research: He is the principal investigator for the OIC Research Facility, where he oversees several phase 1-4 clinical trials. In this capacity, he has presented study results at major international conferences such as the International AIDS Conference, International AIDS Society Conference, Interscience Conference on Antimicrobial Agents and Chemotherapy, and the Conference on Retroviruses and Opportunistic Infections. Dr. DeJesus has remained highly active in Florida's Hispanic HIV community, where he has implemented and supported educational, preventative and research programs. He has participated as a guest speaker for community programs, medical forums and as part of the HIV and infectious diseases training of physicians in medical centers around the country. Disclosures Edwin DeJesus, M.D., F.A.C.P., has received research support from Abbott Laboratories, Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman LaRoche Laboratories, Merck, Pfizer, Schering Plough, Taimed, Tobira, Tibotec and Vertex. He has been a consultant and received honorarium from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec and Vertex Pharmaceuticals. He has served on speakers bureaus for Gilead Sciences, Merck, Tibotec and Virco.

Latest by Edwin DeJesus, M.D.

Promo Image

An Update on New HIV Antiretroviral Agents

Table of Contents

Introduction Etravirine: The First FDA-Approved Second-Generation NNRTI Etravirine Adverse Events Etravirine Dosing Drug Interactions Summary New Protease Inhibitors Darunavir: The First FDA-Approv...

Promo Image
Conference Coverage

Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment

Darunavir (TMC114, Prezista) is the first engineered protease inhibitor (PI) designed specifically to overcome PI-resistant mutations. At the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007), several ...

Promo Image
Conference Coverage

Another Integrase Inhibitor -- Elvitegravir (GS-9137) -- Progresses in Development

Integrase inhibitors continue to be the most exciting agents in the new armamentarium for the treatment of HIV infection. During the past few conferences we have viewed the results of several studies on two compounds that have progressively advanced ...

Promo Image
Conference Coverage

79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16

2007 has the potential to enter history books as the only year in which agents from two new HIV drug classes could receive U.S. Food and Drug Administration (FDA) approval for use in the treatment of HIV infection in the HIV treatment-experienced pop...

Promo Image
Conference Coverage

MK-0518 Demonstrates Potent Efficacy in Patients With Triple-Class-Resistant Virus: 24-Week Results

Once again, the new integrase inhibitor MK-0518 continues to wow us. It dominated the stage at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2006) in San Francisco. ICAAC 2006 is the third major international HIV-re...

Promo Image
Conference Coverage

Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients

Integrase is an HIV enzyme that allows the HIV virus to insert its genetic material into the DNA of human T cells. HIV integrase inhibition is a new mechanism of viral inhibition that blocks this step in the life cycle of HIV, thus preventing HIV fro...

Promo Image
Conference Coverage

Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy

Current U.S. Department of Health and Human Services guidelines1 recommend lopinavir/ritonavir (LPV/r, Kaletra) in combination with lamivudine (3TC, Epivir) or emtricitabine (FTC, Emtriva) and zidovudine (AZT, Retrovir) as a first-line regimen for tr...

Promo Image
Conference Coverage

Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial

Traditionally, an antiretroviral therapy regimen has consisted of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus a third drug, either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI). The ...

Promo Image
Conference Coverage

Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens

Brecanavir (BCV, GW640385) is a new protease inhibitor (PI) in phase 2b clinical development by GlaxoSmithKline (Glaxo). It has shown powerful antiviral activity against both wild-type and highly drug-resistant HIV. One of its main attributes is that...

Promo Image

Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy

Several treatment strategies have been designed to deal with patients whose first regimen is failing. Some of the strategies considered include:

an intensification approach in which a single drug is added to a marginally failing regimen in an attemp...